Citadel Advisors
OPRX icon

Citadel Advisors’s OptimizeRx OPRX Stock Holding History

Citadel Advisors’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Buy
46,700
+17,700
+61% +$164K ﹤0.01% 10521
2025
Q4 		$356K Sell
29,000
-31,200
-52% -$510K ﹤0.01% 9781
2025
Q3 		$1.23M Sell
60,200
-7,000
-10% -$111K ﹤0.01% 7090
2025
Q2 		$907K Buy
67,200
+37,700
+128% +$412K ﹤0.01% 7325
2025
Q1 		$255K Buy
29,500
+17,500
+146% +$107K ﹤0.01% 9939
2024
Q4 		$58.3K Buy
12,000
+11,200
+1,400% +$62.6K ﹤0.01% 12216
2024
Q3 		$6.18K Sell
800
-21,000
-96% -$187K ﹤0.01% 13435
2024
Q2 		$218K Buy
21,800
+19,000
+679% +$209K ﹤0.01% 9751
2024
Q1 		$34K Sell
2,800
-27,100
-91% -$393K ﹤0.01% 12566
2023
Q4 		$428K Buy
29,900
+13,200
+79% +$127K ﹤0.01% 8435
2023
Q3 		$130K Sell
16,700
-79,700
-83% -$867K ﹤0.01% 10562
2023
Q2 		$1.38M Sell
96,400
-60,100
-38% -$856K ﹤0.01% 5828
2023
Q1 		$2.29M Buy
156,500
+81,100
+108% +$1.36M ﹤0.01% 5106
2022
Q4 		$1.27M Sell
75,400
-114,900
-60% -$1.99M ﹤0.01% 6355
2022
Q3 		$2.82M Buy
190,300
+114,000
+149% +$2.25M ﹤0.01% 4926
2022
Q2 		$2.09M Buy
76,300
+28,100
+58% +$833K ﹤0.01% 5455
2022
Q1 		$1.82M Sell
48,200
-49,400
-51% -$2.19M ﹤0.01% 6294
2021
Q4 		$6.06M Buy
97,600
+31,200
+47% +$2.36M ﹤0.01% 3962
2021
Q3 		$5.68M Sell
66,400
-19,600
-23% -$1.23M ﹤0.01% 4064
2021
Q2 		$5.32M Sell
86,000
-19,400
-18% -$987K ﹤0.01% 4300
2021
Q1 		$5.14M Buy
105,400
+62,200
+144% +$3M ﹤0.01% 4201
2020
Q4 		$1.35M Buy
+43,200
New +$1.06M ﹤0.01% 6159

Other funds holding OPRX

WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's OPRX Position: Q1 2026 in Review

Citadel Advisors sold out of OptimizeRx (OPRX) in Q1 2026, closing a stake of 11,976 shares — an estimated $111K sold.

Citadel Advisors first reported a position in OPRX in Q4 2020 and held it in 19 quarters. The position peaked at $2.76M in Q1 2023. 128 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Citadel Advisors reported no remaining OptimizeRx position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 11,976 OptimizeRx shares in Q1 2026, an estimated $111K.
  • Citadel Advisors first reported a position in OptimizeRx in Q4 2020 and held it in 19 quarters.
  • Citadel Advisors's OptimizeRx position peaked at $2.76M in Q1 2023.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.